Role of 18F-FDG PET/CT, 123I-MIBG SPECT, and CT in Restaging Patients Affected by Malignant Pheochromocytoma

Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma

“…In sum, the significant higher diagnostic performance of 68 Ga-DOTATATE PET/ CT, on a per-lesion basis, in comparison with [14,16,26,33]. Whereas, the sensitivity of 18 F-FDG is rather similar on a per-patient basis (90.9 % vs 86-88 %) but is significantly lower on per-lesion basis (51.3 % vs 74 %) [14,16]. These discrepancies may be related to the use of different reference standards in validating the disease.…”

“…In recent years, 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) has been suggested as a preferred functional imaging tool in malignant PCC/PGL, particularly in SDH and von Hippel-Lindau (VHL) germline mutation tumours or when de-differentiated tumour is suspected [15][16][17].…”

Predictors of malignancy in patients with pheochromocytomas/paragangliomas: Asian Indian experience

“…18 F-FDG PET/CT had the best (100%) sensitivity for both skeletal and soft tissue metastases when compared to anatomical imaging (CT-neck to pelvis) (55%) and MIBG (27.78%). Superiority of 18 F-FDG PET/CT over anatomical imaging and MIBG has been demonstrated in most of the other studies ( 5 , 6 , 7 , 8 ). Sensitivities of anatomical imaging and 18 F-FDG PET/CT in our study are similar to the previous reports.…”

“…The latter includes 123 I-metaiodobenzyl guanidine ( 123 I-MIBG), 18 F-flurodeoxyglucose positron emission tomography ( 18 F-FDG PET/CT), 18 F-flurodopamine PET ( 18 F-FDA PET/CT), 18 F-flurodopa PET ( 18 F-FDOPA PET/CT) and 68 Ga-DOTATATE PET/CT ( 3 , 4 ). As compared to anatomical imaging and 123 I-MIBG, 18 F-FDG PET/CT has been proven to be more sensitive in diagnosing metastases ( 5 , 6 , 7 , 8 ). However, 68 Ga-DOTATATE PET/CT has proven to be a superior modality as compared to 18 F-FDG PET/CT in the evaluation of SDHx-associated malignant PCC/PGL ( 3 ).…”

Genetic status determines 18F‐FDG uptake in pheochromocytoma/paraganglioma

“…Due to non‐specific accumulation of fluoro‐2‐deoxy‐ d ‐glucose (FDG) in most types of malignant tumours and many benign inflammatory/infective conditions, its use was not preferred in the past for localisation of metastatic or multifocal PCC/PGL . However, in the last few years, 18 F‐FDG positron emission tomography/computerised tomography ( 18 F‐FDG PET/CT) has been widely used in the evaluation of PCC/PGL, especially in patients with suspected multifocal and malignant tumours and has been recommended as one of the first line functional imaging in this setting . A recent study has demonstrated superiority of 68 Ga‐DOTA(0)‐Tyr(3)‐octreotate (DOTATATE) PET/CT over other functional imaging modalities in the localisation of SDHB ‐associated metastatic pheochromocytoma and paraganglioma .…”